Inovio Pharmaceuticals, Inc. News (NASDAQ:INO)

DateTimeSource
Headline
12/01/20169:00AMGLOBEInovio Pharmaceuticals Awarded $6.1 Million Sub-grant Through Wistar Institute to Develop DNA-based Monoclonal Antibodies Aga...
Grant Provides Funding to Help Prepare New Zika Therapy for Human Trials Inovio Already in Two Human Trials for its Preventive Zika Vaccine PLYMOUTH MEETING, Pa. & PHILADELPHIA, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has been awarded a $6.1 million sub-grant... More...>>
11/25/20168:00AMGLOBEInovio Applies to Cease Reporting to Canadian Securities Regulatory Authorities; NASDAQ Listing and US Reporting Unaffected
PLYMOUTH MEETING, Pa., Nov. 25, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that further to the voluntary delisting of Genetronics Biomedical Corporation, a predecessor of the Company, from the Toronto Stock Exchange on January 17, 2003, it has applied to the British Columbia Securities... More...>>
11/21/20168:00AMGLOBEInovio’s Co-Founder and Chair of its Scientific Advisory Board Selected as a Top 20 Translational Researcher
PLYMOUTH MEETING, Pa., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. David B. Weiner, its co-founder, board member and chair of its scientific advisory board, has been selected as a “Top 20 Translational Researcher” for the year 2015 by the editors of Nature Biotechnology... More...>>
11/16/20168:00AMGLOBEInovio Wins Deloitte’s “Fast 500” Growth Award
PLYMOUTH MEETING, Pa., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced it ranked No. 107 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. Technology Fast... More...>>
11/14/20167:00AMGLOBEInovio’s Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients...
PLYMOUTH MEETING, Pa., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced an interim data analysis showing that its INO-3112 cancer immunotherapy product generated antigen-specific CD8+ killer T cell responses measured both in tumor tissue and in peripheral blood from subjects... More...>>
11/10/201610:00AMGLOBEInovio Pharmaceuticals Zika Vaccine Protects Animals from Infection, Brain Damage and Death
Article published in npj Vaccines demonstrates that DNA vaccine protected 100% of animals from Zika infection after exposure to the virus PLYMOUTH MEETING, Pa., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Inovio and its collaborators have published results in Nature... More...>>
11/09/20167:30AMGLOBEInovio Pharmaceuticals Reports 2016 Third Quarter Financial Results
PLYMOUTH MEETING, Pa., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended September 30, 2016. The following financial results provide a year-over-year comparison of the third quarter in 2016 and 2015. Total revenue was $12.5 million compared... More...>>
11/04/20168:00AMGLOBEInovio Pharmaceuticals to Participate in Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate at the following upcoming investment conferences: Global Mizuho Investor Conference (MIC)One-on-one meetings onlyDr. Niranjan Sardesai, COONovember 14, 2016Omni Berkshire... More...>>
10/26/20168:00AMGLOBEInovio Pharmaceuticals to Report Third Quarter 2016 Financial Results November 9, 2016
PLYMOUTH MEETING, Pa., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to discuss its 2016 third quarter financial results and provide a corporate update on Wednesday, November 9, 2016 at 8:30 a.m. ET. A live and archived version... More...>>
10/24/20168:00AMGLOBEInovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed
PLYMOUTH MEETING, Pa., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its proposed phase III clinical program for VGX-3100. A clinical hold is a notification issued by the FDA to a trial sponsor to... More...>>
10/21/20168:00AMGLOBEInovio CEO Selected As 2016 Healthcare Innovator
PLYMOUTH MEETING, Pa., Oct. 21, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced that its President and Chief Executive Officer, Dr. J. Joseph Kim, has been selected as a 2016 Healthcare Innovator by a panel of scientific and medical experts convened by the Philadelphia Business Journal... More...>>
10/12/20168:00AMGLOBEInovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio
PLYMOUTH MEETING, Pa., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced strategic leadership appointments to support the advancement of its portfolio of DNA-based cancer immunotherapies and infectious disease vaccines. Inovio has an extensive pipeline of clinical-stage cancer... More...>>
09/12/20168:00AMGLOBEInovio’s Zika Vaccine Selected As 2016 Technology Breakthrough
PLYMOUTH MEETING, Pa., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its Zika vaccine in development has been named a 2016 Technology Breakthrough by the editors of Popular Mechanics magazine, the leading technology voice in the U.S. with millions of readers. Inovio has... More...>>
09/01/20169:05AMGLOBEInovio Pharmaceuticals to Present at Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will present a corporate overview at the following upcoming conferences: Citi 11th Annual Biotech ConferenceMandarin Oriental, Boston, Thursday, September 8th, 1x1 meetings 23rd Annual Newsmakers... More...>>
08/29/20167:00AMGLOBEInovio Launches Zika Vaccine Trial in Midst of Puerto Rico Epidemic to Explore Early Signals of Vaccine Efficacy
PLYMOUTH MEETING, Pa., Aug. 29, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced it has initiated a clinical study of its preventive Zika vaccine (GLS-5700) in 160 subjects in Puerto Rico, where the Zika virus outbreak has been declared a public health emergency. The CDC estimates Zika... More...>>
08/16/20168:00AMGLOBEInovio Licenses Veterinary Foot and Mouth Disease Vaccine to Plumbline Life Sciences
PLYMOUTH MEETING, Pa., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced it has licensed a veterinary vaccine for foot and mouth disease (FMD) to Plumbline Life Sciences (KONEX: 222670), an animal health company headquartered in South Korea. Plumbline will fund all development... More...>>
08/11/20168:00AMGLOBEInovio Pharmaceuticals Expands Positive Phase I Ebola Vaccine Trial to Identify Most Optimal Immunization Regimen
PLYMOUTH MEETING, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the company is more than doubling study enrollment to further characterize and identify in humans the most optimal immunization regimen using intradermal (skin) delivery of its preventive Ebola DNA vaccine... More...>>
08/08/20167:30PMGLOBEGeneOne Life Science Announces Full Enrollment of First-In-Human Study of MERS Vaccine
SEOUL, South Korea, Aug. 08, 2016 (GLOBE NEWSWIRE) -- GeneOne Life Science Inc. (KSE:011000) today announced that enrollment has been completed of the first-in-human clinical trial of the GLS-5300 vaccine for MERS (Middle East Respiratory Syndrome) with a total of 75 subjects. GeneOne Life Science and U.S.-based Inovio... More...>>
08/08/20168:00AMGLOBEInovio Pharmaceuticals Reports 2016 Second Quarter Financial Results
PLYMOUTH MEETING, Pa., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended June 30, 2016. The following financial results provide a year-over-year comparison of the second quarter in 2016 and 2015. Total revenue was $6.2 million compared to... More...>>
08/04/20168:00AMGLOBEInovio Pharmaceuticals Appoints Dr. Ami Shah Brown As Vice President Regulatory Affairs
PLYMOUTH MEETING, Pa., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the appointment of Dr. Ami Shah Brown as Vice President Regulatory Affairs. Dr. Brown, who joined Inovio in 2011 as Senior Director of Regulatory Affairs, will be responsible for developing and implementing... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20161202 20:12:19